Trial Profile

A Phase 1/2, Multicenter, Open-Label Study to Investigate the Safety, Tolerability, and Efficacy of a Single Intravenous Dose of SGT-003 in Males With Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 08 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Nov 2025 According to Solid Biosciences media release, the trial is enrolling participants at 15 active clinical trial sites across the US, UK, Italy and Canada.
04 Nov 2025 Interim results presented in the Solid Biosciences media release.
04 Nov 2025 According to Solid Biosciences media release, as of 31 October 2025, 23 patients has been dosed in the study and expects to have dosed 30 participants in total by early 2026. And, company plans to meet with the FDA to discuss potential registrational pathways in first half of 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com